TFAP2A links drug resistance to antitumor immunity
Haiwei Mou, Veronika Yakovishina, Kristen M. DeRosa, Yeqing Chen, Min Xiao, Maggie Dunne, Nancy Shi, Monzy Thomas, Jordan L. Smith, Qin Liu, Meenhard Herlyn
This study identifies TFAP2A as a driver of BRAF/MEK inhibitor resistance and immunosuppression, showing its disruption enhances antitumor immunity and overcomes drug resistance.
bioRxiv · Jul 10, 2026 · PreprintCancer Biology